Amendment: SEC Form SC 13G/A filed by Novavax Inc.
$NVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2025 | $18.00 | Overweight | Cantor Fitzgerald |
| 8/28/2025 | $10.00 | Buy | H.C. Wainwright |
| 8/20/2025 | $7.00 | Neutral → Underperform | BofA Securities |
| 6/17/2025 | $6.00 | Sell | Citigroup |
| 2/28/2025 | $19.00 | Buy | BTIG Research |
| 7/30/2024 | $8.00 | Neutral → Underweight | JP Morgan |
| 5/10/2024 | $4.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 5/10/2024 | Underweight → Neutral | JP Morgan |
GAITHERSBURG, Md., June 1, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference.Conference Details:Fireside ChatDate:Thursday, June 4, 2026Time:10:30 – 11:00 a.m. Eastern Time Location:New York, NYRecordingsA webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days.About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-base
GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.Conference Details:Fireside ChatDate:Wednesday, May 13, 2026Time:3:00 – 3:30 p.m. Pacific TimeLocation:Las Vegas, NVConferenceEvent:Investor MeetingsDate:Wednesday, May 13, 2026A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days.About NovavaxNovavax, Inc. tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including
Total revenue of $140 million in the first quarter of 2026Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious disease areas In April, Novavax signed a new MTA with a top 10 leading pharmaceutical company and leader in oncology to explore Matrix-M in multiple oncology and infectious disease targets In April, Novavax expanded an existing partnership with a new MTA, providing access to Matrix-M for exploration in up to nine additional identified infectious diseasesIn February, Novavax expanded an existing MTA with a major global pharmaceutical company to explore an additional field and signed a new MTA with an oncology companySanofi announced p
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
3 - NOVAVAX INC (0001000694) (Issuer)
8-K - NOVAVAX INC (0001000694) (Filer)
10-Q - NOVAVAX INC (0001000694) (Filer)
SCHEDULE 13G/A - NOVAVAX INC (0001000694) (Subject)
Cantor Fitzgerald resumed coverage of Novavax with a rating of Overweight and set a new price target of $18.00
H.C. Wainwright resumed coverage of Novavax with a rating of Buy and set a new price target of $10.00
BofA Securities downgraded Novavax from Neutral to Underperform and set a new price target of $7.00
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of
For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO
Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi
GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp
Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
Total revenue of $140 million in the first quarter of 2026Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious disease areas In April, Novavax signed a new MTA with a top 10 leading pharmaceutical company and leader in oncology to explore Matrix-M in multiple oncology and infectious disease targets In April, Novavax expanded an existing partnership with a new MTA, providing access to Matrix-M for exploration in up to nine additional identified infectious diseasesIn February, Novavax expanded an existing MTA with a major global pharmaceutical company to explore an additional field and signed a new MTA with an oncology companySanofi announced p
GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the event and replay are as follows:Conference call details:Date:May 6, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can also dial direct to be enter
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&